Literature DB >> 2853321

Motivational effects of opioids in an animal model of prolonged inflammatory pain: alteration in the effects of kappa- but not of mu-receptor agonists.

T S Shippenberg1, C Stein, A Huber, M J Millan, A Herz.   

Abstract

An unbiased preference conditioning procedure was used to characterize and compare the motivational effects of opioids in naive rats and those suffering from the prolonged pain associated with Freund's adjuvant (FA)-induced inflammation of one hind limb. The mu-opioid agonist morphine functioned as a reinforcer in naive animals, producing marked preferences for the drug-paired place. Similarly, rats injected with FA 7 days prior to conditioning exhibited a preference for the morphine place, and the magnitude of this effect did not differ between groups. Administration of the kappa-opioid receptor agonist U-69593 to naive rats produced dose-related place aversions. The aversive effect of this kappa-agonist was, however, abolished in FA-treated rats. Thus, regardless of the dose administered, U-69593 produced conditioning similar to that observed in response to saline. These data suggest that kappa-agonists may lack aversive effects in subjects experiencing prolonged noxious stimulation, and as such may be effective therapeutic agents in the management of chronic pain states.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2853321     DOI: 10.1016/0304-3959(88)90225-4

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  21 in total

1.  Effects of paclitaxel on mechanical sensitivity and morphine reward in male and female C57Bl6 mice.

Authors:  Harshini Neelakantan; Sara Jane Ward; Ellen Ann Walker
Journal:  Exp Clin Psychopharmacol       Date:  2016-12       Impact factor: 3.157

2.  Elevation of Transient Receptor Potential Vanilloid 1 Function in the Lateral Habenula Mediates Aversive Behaviors in Alcohol-withdrawn Rats.

Authors:  Danielle M Gregor; Wanhong Zuo; Rao Fu; Alex Bekker; Jiang-Hong Ye
Journal:  Anesthesiology       Date:  2019-04       Impact factor: 7.892

Review 3.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

4.  Effects of repeated morphine on intracranial self-stimulation in male rats in the absence or presence of a noxious pain stimulus.

Authors:  Laurence L Miller; Ahmad A Altarifi; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2015-08-10       Impact factor: 3.157

5.  Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.

Authors:  Vanessa Minervini; Sujata Dahal; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2016-11-30       Impact factor: 4.030

6.  Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures.

Authors:  Vanessa Minervini; Hannah Y Lu; Jahnavi Padarti; Daniela C Osteicoechea; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2018-05-22       Impact factor: 4.530

7.  CI-977, a novel and selective agonist for the kappa-opioid receptor.

Authors:  J C Hunter; G E Leighton; K G Meecham; S J Boyle; D C Horwell; D C Rees; J Hughes
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

8.  Punishment and reinforcement by opioid receptor agonists in a choice procedure in rats.

Authors:  Vanessa Minervini; Daniela C Osteicoechea; Angelo Casalez; Charles P France
Journal:  Behav Pharmacol       Date:  2019-06       Impact factor: 2.293

Review 9.  A Neurobehavioral Approach to Addiction: Implications for the Opioid Epidemic and the Psychology of Addiction.

Authors:  Antoine Bechara; Kent C Berridge; Warren K Bickel; Jose A Morón; Sidney B Williams; Jeffrey S Stein
Journal:  Psychol Sci Public Interest       Date:  2019-10

Review 10.  The application of conditioning paradigms in the measurement of pain.

Authors:  Jun-Xu Li
Journal:  Eur J Pharmacol       Date:  2013-03-13       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.